retatrutide hfpef trial Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity STEP HFpEF DM: a sweet

VitaGleam D3 : Delivers vitamin D3 to support bone health, immune function, and mood regulation, its especially important for those with vitamin D deficiencies

ISSN 2168-8184

Key Observations from Phase 2 Data Dose escalation reduced adverse events: Groups that used gradual dose titration reported fewer GI events than those starting at the target dose directly No deaths were attributed to the study drug Serious adverse events were reported at low rates across all groups, with no clear dose-dependent pattern for serious events The placebo group also reported substantial adverse events (72.1%), which is typical for trials of this size and duration TRIUMPH Phase 3 Adverse Event Profiles The TRIUMPH program consists of eight Phase 3 trials evaluating retatrutide across multiple indications including obesity, type 2 diabetes, and metabolic-associated steatotic liver disease (MASLD)

Since elevated liver enzymes can be a concerning side effect for individuals taking GLP-1 receptor agonists, liver function should be monitored regularly